¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Xenograft Model Antitumor Assays"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç×¾ÏÁ¦
  • xenograft
    1. ÀÌÁ¾ÀÌ½Ä 2. ÀÌÁ¾ÀÌ½ÄÆí
  • animal model
    µ¿¹°¸ðÇü
  • atomic model
    ¿øÀÚ¸ðÇü
  • additive model
    µ¡¼À¸ðµ¨
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartment model
    ±¸È¹¸ðµ¨
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü
  • demonstration model
    ½Ã¹ü¸ðÇü
  • fluid mosaic model
    À¯µ¿¸ðÀÚÀÌÅ©¸ðµ¨
  • general linear model
    ÀϹݼ±Çü¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
  • health belief model
    °Ç°­¹ÏÀ½¸ðÇü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç×¾ÏÁ¦
  • xenograft
    ÀÌÁ¾À̽Ä
  • model
    ¸ðÇü, ¸ðµ¨
  • animal model
    µ¿¹°¸ðÇü
  • plaster model
    ¼®°í¸ðÇü
  • symmetry model
    ´ëĪÇü, ´ëμ³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç×¾ÏÁ¦
  • xenograft
    ÀÌÁ¾À̽Ä
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • additive model
    µ¡¼À¸ðµ¨
  • animal model
    µ¿¹°¸ðÇü
  • atomic model
    ¿øÀÚ¸ðÇü
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartment model
    ±¸È¹¸ðµ¨
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü
  • demonstration model
    ½Ã¹ü¸ðÇü
  • fluid mosaic model
    À¯µ¿¸ðÀÚÀÌÅ©¸ðµ¨
  • general linear model
    ÀϹݼ±»ó¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
  • health belief model
    °Ç°­¹ÏÀ½¸ðÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
  • antitumor agent
    Ç׾Ͼà(ù÷äßå·), Ç×Á¾¾ç(¼º)¾à.
  • antitumor agent
    Ç׾Ͼà(ù÷ å·), Á¦¾Ï¾à(ð¤ å·), Ç×Á¾¾ç(¼º)¾à(ù÷ðþåËàõå·), Ç×Á¾¾ç(¼º)ÀÎÀÚ.
  • antitumor antibiotic
    Ç×Á¾¾ç(¼º) Ç×»ý¹°Áú(¡­(àõ) ù÷ßæÚªòõ).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • ITE =in the ear model
    ±Í¼ÓÇü(º¸Ã»±â)
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • gnathostatic model
    ¾ÇŸðÇü(¡­Ù¼úþ).
  • health belief model
    °Ç°­¹ÏÀ½ ¸ðÇü.
  • homeostatic model
    Ç×»ó¼º ¸ðÇü(Ù¼úþ)<Ç¥ÁØÇü>
  • in-the-ear model
    ±Í¼ÓÇü(º¸Ã»±â)
  • plaster model
    ±é½º Çü(¡­úþ), ¼®°í ¸ðÇü.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • xenograft
    ÀÌÁ¾À̽Ä
  • xenograft =heterograft
    ÀÌÁ¾À̽Ä(ÀÌÁ¾À̽Ä).
  • xenograft =heterograft
    ÀÌÁ¾À̽Ä(ì¶ðúì¹ãÕ).
  • antitumor agent
    Ç׾Ͼà(ù÷äßå·), Ç×Á¾¾ç(¼º)¾à.
  • antitumor agent
    Ç׾Ͼà(ù÷ å·), Á¦¾Ï¾à(ð¤ å·), Ç×Á¾¾ç(¼º)¾à(ù÷ðþåËàõå·), Ç×Á¾¾ç(¼º)ÀÎÀÚ.
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
  • antitumor antibiotic
    Ç×Á¾¾ç(¼º) Ç×»ý¹°Áú(¡­(àõ) ù÷ßæÚªòõ).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • cytotoxic antitumor antibody
    ¼¼Æ÷µ¶¼ºÇ×Á¾¾çÇ×ü
  • immunity, antitumor
    Ç×Á¾¾ç¸é¿ª
  • k cell,antitumor
    Ç×Á¾¾ç(ù÷ðþåË)
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • atomic model
    ¿øÀÚ¸ðÇü(¡­Ù¼úþ).
  • biopsychological model
    »ýü½É¸®ÇÐÀû ¸ðµ¨
  • bulk phase model
    µ¢¾î¸® À§»ó ¸ðÇü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • xenograft
    ÀÌÁ¾ÀÌ½ÄÆí(ì¶ðúì¹ãÕø¸)
  • antitumor antibiotics
    Ç×Á¾¾ç Ç×»ýÁ¦(ù÷ðþåËù÷ßæð¥)
  • antitumor antimetabolite
    Ç×Á¾¾ç Ç×´ë»ç¹°(ù÷ðþåËù÷ÓÛÞóÚª)
  • antitumor enzyme
    Ç×Á¾¾ç È¿¼Ò(ù÷ðþåËý£áÈ)
  • antitumor protein
    Ç×Á¾¾ç ´Ü¹éÁú(ù÷ðþåËÓ±ÛÜòõ)
  • alternate-site model
    ±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
  • asymmetric strand transfer model
    ºñ´ëĪ(ÞªÓßöà) °¡´ÚÀüÀÌ(ï®ì¹) ¸ðµ¨
  • ball and stick model
    °ø ¸·´ë ¸ðµ¨
  • Benson model
    º¥¼Õ ¸ðµ¨
  • bilayer model
    À̺ÐÀÚÃþ(ì£ÝÂí­öµ) ¸ðµ¨
  • breakage and reunion model
    Àý´ÜÀç°áÇÕ(ï·Ó¨î¢Ì¿ùê)¸ðµ¨
  • Britten-Davidson model
    ºê¸®Æ°-´ëºñ½¼ ¸ðµ¨
  • Cairns model
    Äɸ¥½º ¸ðµ¨
  • Campbell model
    Ä·º§ ¸ðµ¨
  • cloverleaf model
    Ŭ·Î¹öÀÙ ¸ðµ¨
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç׾Ͼà, Á¦¾Ï¾à
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • general linear model
    ÀϹÝÀû ¼±Çü¸ðµ¨, ÀÏ¹Ý ¼±»ó¸ðµ¨
  • model
    ¸ðÇü, Ç¥ÁØÇü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ROATS rabbit ovarian antitumor serum
CPK cell population kinetic [model]; creatine phosphokinase
GHPM general health policy model
GLIM generalized linear interactive model
GLM general linear model
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DXR Delayed xenograft rejection
Xg xenograft
DAS-ELISA Double antibody sandwich enzyme-linked immunosorbent assays
EMSA Electromobility shift assays
IEMA immuno-enzymometric assays
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • model spray ¸ðÇü»ó¿¡ Ç¥½ÃÇÑ ¿¬ÇÊ ¼±ÀÌ Áö¿öÁöÁö ¾Ê°Ô Çϱâ À§ÇØ »ç¿ëµÇ´Â Àç·á.

    model trimmer

    ¸ðÇü ´Ùµë±â, ¸ðÇü »èÇÕ±â
    ¸ðÇüÀ» »èÁ¦ÇÏ¿© ÀÏÁ¤ÇÑ ±Ô°ÝÀ¸·Î Á¦ÀÛÇϱâ À§ÇØ »ç¿ëÇÏ´Â ±â±¸.
  • xenograft
    ÀÌÁ¾À̽Ä, ÀÌÁ¾ÀÌ½ÄÆí, ÀÌÁ¾Á¶Á÷À̽Ä
    µ¿ÀǾî=heterograft. ÀÌÁ¾ µ¿¹°°£¿¡ À̽ĵǴ Á¶Á÷Æí.
  • antitumor agent
    Ç׾Ͼà, Á¦¾Ï ¾à, Ç×Á¾¾ç ¾à, Ç×Á¾¾ç¼º ¾à, Ç×Á¾¾ç ÀÎÀÚ, Ç×Á¾¾ç¼º ÀÎÀÚ
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • biomedical model
    »ýÀÇÇÐÀû ¸ðµ¨
  • biopsychosocial model
    »ý¹° »çȸ ½É¸® ¸ðÇü
  • casting model
    ÁÖÁ¶ ¸ðÇü
    µ¿ÀǾî=refractoryc cast. ³³ÇüÀÌ ¸Å¸ôÁ¦¿¡ ÀÇÇØ ¸Å¸ôµÇ¾î ÀÖ´ø ºÎºÐÀ¸·Î ¸Å¸ôÁ¦¿¡ ÀÇÇØ Çü¼ºµÈ °ÍÀ¸·Î ÁÖÁ¶ ½Ã ¿ëÀ¶µÈ ±Ý¼ÓÀÌ Èê·¯ µé¾î°¥ ¼ö ÀÖ´Â ºó °ø°£À» ¸»ÇÑ´Ù.
  • computer simulation model
    ¸ðÀÇ ÄÄÇ»ÅÍ ¸ðÇü
  • conceptual model
    °³³äÀû ¸ðÇü
  • deletion model
    °á½Ç ¸ðµ¨
    µ¹¿¬º¯ÀÌÀÇ ÇϳªÀ̸ç À¯Àü ¹°ÁúÀÇ ÀϺκÐÀÌ °á¿©µÇ¾î ÀÖ´Â °Í. ¸é¿ª À¯ÀüÇп¡¼­´Â ¸é¿ª ±Û·ÎºÎ¸°ÀÇ H¼â À¯ÀüÀÚ±ºÀ» ÆÇµ¶ÇÏ´Â ±â±¸·Î¼­ÀÇ ´ë¸³ À¯ÀüÀÚ °á½Ç ¸ðµ¨ÀÌ À¯¸íÇÏ´Ù.
  • in the ear model
    ±Í¼ÓÇü
  • integrating conceptual model
    ÅëÇÕ °³³ä ¸ðÇü
  • model
    ¸ðµ¨, º»º¸±â, ¸ðÇü, Ç¥ÁØÇü
    Áø´ÜÇÐ ¶Ç´Â ÇØºÎÇÐ ¿¬±¸¿ëÀÇ ¸ðÇü°ú °°ÀÌ ´Ù¸¥ ¹°°ÇÀ» Ç¥ÇöÇÏ´Â °Í Ä¡°úÇп¡¼­ÀÇ ÁÖÇü Ç¥º».
  • model base
    ¸ðÇü Àú¸é
    ¸ðÇüÀÇ ¹Ø¸é.
  • model mounting
    ¸ðÇü ºÎÂø
    ÀÛ¾÷ ¸ðÇü°ú ´ëÇÕ Ä¡¿­ ¸ðÇüÀ» ±³Çձ⿡ ºÎÂø½ÃŰ´Â °úÁ¤.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
xenograft <surgery> A surgical graft of tissue from one species onto or into individuals of unlike species, genus or family. Also know as a heteroplastic graft.
See: xenotransplantation.
(11 May 1997)
chemiluminescence assays Including a subcategory using bioluminescence (biologically derived chemiluminescence agents), use the generation of light from oxidative chemical reactions as an indicator of the quantity of unbound luminescent labelled antigen. This allows quantitation of unlabelled antigen from patient specimens in a variety of homogeneous (single phase) or heterogeneous (multiple phase) immunoassay techniques.
(05 Mar 2000)
drug screening assays, antitumour Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals.
(12 Dec 1998)
Adair-Koshland-Nemethy-Filmer model <biochemistry, chemistry> A model to explain the allosteric form of cooperativity; in this model, in the absence of ligands, the protein exists in only one conformation; upon binding, the ligand induces a conformational change that may be transmitted to other subunits.
Synonym: Adair-Koshland-Nemethy-Filmer model, induced fit model.
(05 Mar 2000)
additive model A model in which the combined effect of several factors is the sum of the effects that would be produced by each of the factors in the absence of the others.
(05 Mar 2000)
age-structured model <epidemiology> A mathematical model which take into consideration the division of the host population into different age classes. Such models can used to consider the consequences of such factors as age-dependent infection, morbidity or mortality rates or of age-specific vaccination schedules.
(05 Dec 1998)
animal model Study in a population of laboratory animals that uses conditions of animals analogous to conditions of humans to simulate processes comparable to those that occur in human populations.
(05 Mar 2000)
Bingham model A model representing the flow behaviour of a Bingham plastic, in the idealised case.
(05 Mar 2000)
biomedical model A conceptual model of illness that excludes psychological and social factors and includes only biological factors in an attempt to understand a person's medical illness or disorder.
(05 Mar 2000)
biopsychosocial model A conceptual model that assumes that psychological and social factors must also be included along with the biological in understanding a person's medical illness or disorder.
(05 Mar 2000)
genetic model A formalised conjecture about the behaviour of a heritable structure in which the component terms are intended to have literal interpretation as standard structures of empirical genetics.
(05 Mar 2000)
mathematical model <epidemiology> A formal framework to convey ideas about the components of a host-parasite interaction. Construction requires three major types of information: (a) a clear understanding of the interaction within the individual host between the infectious agent and the host, (b) the mode and rate of transmission between individuals, and (c) host population characteristics such as demography and behaviour.
Mathematical models can aid exploration of the behaviour of the system under various conditions from which to determine the dominant factors generating observed patterns and phenomena. They also aid data collection and interpretation and parameter estimation, and provide tools for identifying possible approaches to control and for assessing the potential impact of different intervention measures.
(05 Dec 1998)
catalytic model <epidemiology> A (rather misleading name for a) type of compartmental model in which the force of infection is treated as a parameter to be estimated.
(05 Dec 1998)
pathological model An animal or animal stock that by inheritance or by artificial manipulation develops a disorder similar to some disease of interest and hence directly or by analogy furnishes evidence of its pathogenesis and may be used as a model for the study of preventive or therapeutic measures.
(05 Mar 2000)
medical model A set of assumptions that views behavioural abnormalities in the same framework as physical disease or abnormalities.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Xenograft Model Antitumor Assays - »õâ In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
    Synonyms : Antitumor Assays, Xenograft Model, Antitumor Assay, Xenograft, Antitumor Assays, Xenograft, Assay, Xenograft Antitumor, Assays, Xenograft Antitumor, Xenograft Antitumor Assay
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor
    Á¦¾Ï¼ºÀÇ;Ç×Á¾¾ç¼ºÀÇ
  • model
    ¿øÇü
  • Model T
    ¹ß´Þ ÃʱâÀÇ;±¸½ÄÀÇ
  • computer model
    ÄÄÇ»ÅÍ ¸ðµ¨(½Ã¹Ä·¹ÀÌ¼Ç µî¿¡¼­ ½Ã½ºÅÛÀ̳ª ÇÁ·ÎÁ§Æ®ÀÇ ³»¿ë µ¿ÀÛÀ» ÇÁ·Î±×·¥È­ÇÑ °Í)
  • economic model
    (°æ)°æÁ¦ ¸ðµ¨
  • fashion model
    ÆÐ¼Ç ¸ðµ¨
  • floor model
    (Ź»óÇü¿¡ ´ëÇÏ¿©) ¸¶·çÇü;ÄܼÖÇü;(»óÁ¡ÀÇ) Àü½Ãǰ (±â±¸ µî)
  • macroeconomic model
    °Å½ÃÀû °æÁ¦ ¸ðµ¨
  • model
    ¸ðÇü;¿øÇü;º»;¼³°èµµ;¸ðµ¨;¸¶³×Ų;¸ð¹ü;¸ð¹üÀûÀÎ;¸ðÇüÀÇ;¸ð¾çÀ» ¸¶µé´Ù(Á¡Åä µûÀ§¸¦ ¾î¶² ÇüÀ¸·Î)¶ß´Ù;¼³°èÇÏ´Ù;...À» º»¶ß´Ù;model school ½Ã¹ý Çб³)
  • model builder
    °æÁ¦ ¸ðµ¨ÀÇ ÀÛ¼ºÀÚ
  • model building
    ¸ðµ¨ ±¸¼º
  • model(l)er
    ¸ðÇü(¼Ò»ó)À» ¸¸µå´Â »ç¶÷
  • role model
    ¿ªÇÒ ¸ðµ¨
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á